



HHS Public Access

Author manuscript

Clin Sci (Lond). Author manuscript; available in PMC 2019 August 20.

Published in final edited form as:

Clin Sci (Lond). 2018 April 30; 132(8): 851–868. doi:10.1042/CS20171620.

‘Small vessels, dementia and chronic diseases – molecular mechanisms and pathophysiology’

Karen Horsburgh,

Centre for Discovery Brain Sciences, University of Edinburgh

Joanna Wardlaw,

Centre for Clinical Brain Sciences, Dementia Research Institute, University of Edinburgh

Tom van Agtmael,

Institute of Cardiovascular and Medical Sciences, University of Glasgow

Stuart Allan,

Faculty of Biology, Medicine and Health, University of Manchester

Mike Ashford,

School of Medicine, University of Dundee

Philip M Bath,

Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham

Rosalind Brown,

Centre for Clinical Brain Sciences, University of Edinburgh

Jason Berwick,

Department of Psychology The University of Sheffield

M. Zameel Cader,

Nuffield Department of Clinical Neurosciences, University of Oxford

Roxana O Carare,

Faculty of Medicine, University of Southampton

John B Davies,

Alzheimer’s Research UK Oxford Drug Discovery Institute, University of Oxford

Jessica Duncombe,

Centre for Discovery Brain Sciences, University of Edinburgh

Tracy D Farr,

School of Life Sciences, Nottingham University

Jill Fowler,

Centre for Discovery Brain Sciences, University of Edinburgh

Joziën Goense,

CONFLICTS OF INTEREST

ZC has received honoraria and consultancy fees from TEVA, Novartis, Orion, Daichii Sankyo, Allergan

Institute of Neuroscience and Psychology, University of Glasgow

Alessandra Granata,

Department of Clinical Neurosciences, University of Cambridge

Catherine Hall,

School of Psychology, University of Sussex

Atticus Hainsworth,

Molecular and Clinical Sciences Research Institute, St Georges University of London

Adam Harvey,

Institute of Cardiovascular and Medical Sciences, University of Glasgow

Cheryl Hawkes,

Faculty of Science, Technology, Engineering & Mathematics, Open University

Anna Joutel,

Genetics and Pathogenesis of Cerebrovascular Diseases, INSERM, Université Paris Diderot-Paris 7, Paris, France.

Rajesh Kalaria,

Institute of Neuroscience Newcastle University

Patrick G. Kehoe,

Bristol Medical School, , University of Bristol

Catherine Lawrence,

Faculty of Biology, Medicine and Health, University of Manchester

Andy Lockhart,

GSK (currently Heptares Therapeutics)

Seth Love,

Clinical Neurosciences, University of Bristol

Malcolm Macleod,

Centre for Clinical Brain Sciences, University of Edinburgh

Mhairi Macrae,

Institute of Neuroscience and Psychology, University of Glasgow

Hugh Stephen Markus,

Department of Clinical Neurosciences, University of Cambridge

Chris McCabe,

Institute of Neuroscience and Psychology, University of Glasgow

Barry W McColl,

The Roslin Institute & R(D)SVS, UK Dementia Research Institute, University of Edinburgh

Paul James Meakin,

Division of Molecular & Clinical Medicine, School of Medicine, University of Dundee

Alyson Miller,

Institute of Cardiovascular and Medical Sciences, University of Glasgow

Maiken Nedergaard,

University of Rochester Medical Center and University of Copenhagen's Center of Basic and Translational Neuroscience.

Michael O'Sullivan,

Mater Centre for Neuroscience and Queensland Brain Institute, Brisbane, Australia

Terry Quinn,

Institute of Cardiovascular and Medical Sciences, University of Glasgow

Rikesh Rajani,

Genetics and Pathogenesis of Cerebrovascular Diseases, INSERM, , Université Paris Diderot-Paris 7, Paris, France.

Lisa Saksida,

Robarts Research Institute, Western University, London, Ontario

Colin Smith,

Centre for Clinical Brain Sciences, University of Edinburgh

Kenneth J. Smith,

Department of Neuroinflammation, UCL Institute of Neurology, London

Rhian Touyz,

Institute of Cardiovascular and Medical Sciences, University of Glasgow

Rebecca C. Trueman,

School of Life Sciences, Nottingham University

Tao Wang,

Faculty of Biology, Medicine and Health, University of Manchester

Anna Williams,

MRC Centre for Regenerative Medicine, University of Edinburgh

Steve Williams,

Institute of Psychiatry, Kings College London

Lorraine Work

Institute of Cardiovascular and Medical Sciences, University of Glasgow

INTRODUCTION

Cerebral small vessel disease (SVD) is a major health challenge. Therapeutic approaches remain limited, hampered by the lack of mechanistic understanding and identification of therapeutic targets. Relevant animal models could provide a cornerstone to basic scientific studies of disease mechanisms and pre-clinical studies of potential therapies, but there is a critical need to improve the current translational gap that exists between pre-clinical research and treatments in patients. The Medical Research Council Dementias Platform UK (MRC DPUK) Vascular Experimental Medicine Theme identified that a comprehensive assessment

of the latest developments in animal models and of their contribution to understanding of cerebral microvascular disease would reduce the translational gap. In response to this, a two day workshop took place in late January 2017 at the British Heart Foundation Centre of Research Excellence in Glasgow, Scotland in conjunction with MRC DPUK and brought together experts from several disciplines in cerebrovascular disease, dementia and cardiovascular biology, to highlight current advances in these fields, explore synergies and scope for development. There were presentations from UK and international researchers and a specific focus on animal models of cerebral microvascular disease and dementia, considering vascular biology, neuroglial coupling, blood-brain barrier function, neuroinflammation, cerebral drainage pathways, and methodological and translational challenges. This overview provides a summary of the key talks and outcomes of discussion groups about the gaps and opportunities as highlighted by the workshop participants (see Figure 1 for the general organisation of the meeting including the key topics and themes discussed). Additional related articles are published in the Special Edition of Clinical Science (<http://www.portlandpresspublishing.com/cc/small-vessels>).

CEREBRAL VASCULAR DISEASE: CLINICAL CONTEXT

Of the approximate 17 million strokes per year worldwide, 20–25% are due to small vessel disease (SVD). Additionally, a large burden of silent SVD contributes to up to 45% of the 35–42 million new cases of dementia globally each year. SVD is difficult to research, small vessel stroke being neglected in stroke research, and vascular causes are neglected in dementia research. Human pathology often reflects late disease stages with few relevant experimental models identified [1,2] Consequently, treatment is empirical and probably suboptimal. The individual SVD features on neuroimaging are now well-described with standardised terminology [3]. These include acute (recent) small subcortical infarcts and clinically covert features (lacunes, white matter hyperintensities (WMH), microbleeds, perivascular spaces, microinfarcts, and cerebral atrophy), and many haemorrhagic strokes. From early neuropathology studies onwards, SVD has been the vascular lesion most strongly associated with vascular cognitive impairment (VCI) [4], an observation confirmed consistently through more recent large cohort studies of donated brain tissue, showing that neuropathological SVD is associated with cognitive impairment [5]

SVD features are associated with age and several vascular risk factors (hypertension, smoking, diabetes, hypercholesterolemia), but vascular risk factors explain only a small proportion of the variance [6] leaving a large proportion unexplained. Potential pathophysiological mechanisms include vessel stiffening, blood brain barrier failure, poorer pre-morbid white matter integrity [7,8] a cross-sectional association with reduced cerebral blood flow [9,10], and several underlying genetic contributors [11].

Progress in reducing SVD requires questioning of conventional wisdom. Firstly, the effects of SVD on the brain are both diffuse and more dynamic than appreciated previously [12,13]. Subcortical lesions have remote effects; lesions can appear silently or cause symptoms, or can resolve completely, cavitate, or form a WMH [14]. WMH, lacunes and microbleeds may increase, but also decrease [15,16] which suggests that these lesions do not indicate permanent brain damage only. Perivascular spaces are crucial for cerebral interstitial fluid

drainage and waste clearance [17]. They are a site of inflammation and amyloid protein build-up, linking to Alzheimer's disease. Other cell types and structures are involved in SVD, not just the vascular endothelium and smooth muscle cells, but also microglia, astrocytes, oligodendrocytes, pericytes, matrix proteins all play a role. Finally, data from humans and experimental models (see below) indicate a vulnerability to SVD in part [18] explaining why vascular risk factor exposure in some people is far more devastating than in others.

CEREBRAL VASCULAR DISEASE: RODENT MODELS

Whilst there is no one model that captures the complexities of SVD and VCI, different animal models have been studied that encompass many hypothesised causes (e.g. SVD); hypoxic hypoperfusion injury secondary to large artery disease; or genetic influences (see recent review [2] and previous systematic review [19]).

A widely studied model is the spontaneously hypertensive stroke prone (SHRSP) rat which develops malignant hypertension. This model has been reported to develop SVD-like features including white matter changes, lipohyalinosis and fibrinoid necrosis [20,21]. Endothelial and the earliest measured myelin changes have also been shown to predate hypertension [22]. Analysis of gene and protein expression before the onset of hypertension highlighted several genes and proteins associated with SVD and pathways that may underlie these changes (e.g. matrix and vascular integrity, inflammation), and suggests a potential predisposition of SHRSPs to development of SVD-like pathology which is later exacerbated by hypertension [23]. However these findings vary and others have failed to identify white matter damage in older SHRSP in the absence of stroke [24] and in other models of hypertension such as an inducible transgenic model [25]. Additional factors, such as added dietary salt, hypoperfusion and high fat diet have been shown to exacerbate white matter pathology in SHRSP [26] similar to such factors accelerating human SVD.

Alternative models of hypertension have been developed including the effects of angiotensin (ANG) administration. Low doses of angiotensin-II (ANGII) in rodents results in a slow-developing rise in blood pressure which impairs neuroglial vascular (NGVU) coupling and endothelial responses before the onset of hypertension and in the absence of SVD like changes [27]. More recently, simultaneous administration of ANGI and L-NAME (NG-nitro-L-arginine methyl ester) led to chronically elevated blood pressure and produced early SVD-like features [28]. Key features relevant to human SVD were reported in this model including hypertrophy of the cerebral vessel wall, structural impairment of the NGVU, hippocampal atrophy, blood brain barrier (BBB) impairment and occasional microinfarcts and microbleeds.

To investigate vascular insufficiency as a central mechanism in the pathophysiology of VCI, models of cerebral hypoperfusion were developed [29]. These models have been refined over the years to induce hypoperfusion whilst avoiding severe reductions in blood flow that would cause immediate ischaemia. The recent models involve stenosis of the common carotid arteries which immediately restricts blood flow to the forebrain on application of microcoils [30], or gradually restricts blood flow by the use of constrictor devices [31].

These models have been widely studied with behavioural measures of cognition which demonstrate particular impairments in spatial working memory reminiscent of the disrupted frontal cortical circuitry found in VCI [29, 32]. In these models, reduced perfusion is thought to cause a slowly evolving diffuse white matter pathology that can be detected using a variety of approaches such as immunohistochemistry and in vivo magnetic resonance imaging (MRI). The oxygen levels are reduced to hypoxic levels in white matter, which is thought to be the main driver of the ensuing pathological changes [29]. These models have been widely studied to understand the pathophysiology of hypoperfusion-induced white matter changes that are often accompanied by indices of inflammation. Carotid stenosis induced using microcoils in the mouse has also been shown to culminate in marked changes to microvascular structure, BBB breakdown, glio-vascular damage and microinfarcts/microbleeds relevant to human SVD [33]. These studies are predominantly conducted in C57Bl/6J mice which have poor collateral flow through the Circle of Willis and the resultant effects of microcoil/constrictor application assigned to reduced cerebral perfusion. However other, albeit ill-defined, effects on vascular stiffness/pulsatility and cerebrospinal fluid (CSF) drainage may also contribute to the pathology. In a longitudinal study in humans, there is an absence of a direct association between carotid stenosis and WMH or cognitive decline and instead a link with vascular stiffness [34].

Notably, these models of carotid stenosis and hypertension often lack the overt white matter lesions (WML) characteristic of SVD. However, WML are difficult to detect pathologically and a combination of different risk factors may be required to produce WML. As indicated above, the effects of hypoperfusion and diet have been studied in the SHRSP model [26] which exacerbate white matter changes, as compared to individual factors, and precipitate overt WML. Models with co-morbidities may more accurately reflect clinical SVD and be considered as a basis for testing therapeutic interventions.

A number of different mouse models that express highly penetrant gene mutations linked to familial SVD (*NOTCH3*, *COL4A1*, *COL4A2*, *HTRA1*) have provided important insights into causal pathways related to these gene mutations. Interestingly, investigation of these models has now indicated that these different gene mutations may lead to common convergent pathways involving the impairment of extracellular matrix (ECM) function [35]. Further genome wide association studies (GWAS) have shown common variants associated with familial SVD, such as *COL4A1/4A2*, are also risk factors for common sporadic SVD [36]. Thus, an emerging view is that these models may be useful for probing mechanisms important not only in rare monogenic forms of SVD, but also in the more common sporadic forms of SVD, opening up avenues of potential therapeutic intervention.

Both vascular and Alzheimer's disease pathologies appear to work synergistically to promote neurodegeneration and cognitive impairments [37]. Further, there is considerable overlap between risk factors for cerebral microvascular disease, cardiovascular disease and Alzheimer's disease, and yet the synergies between these areas are so far largely unexplored in models. Animal models could provide a powerful basis to tease out molecular interactions. Amyloid is believed to be a key driver of the pathophysiology of AD so most work has focused on models that accumulate amyloid in the brain. Rodents do not naturally develop and deposit amyloid, but genetically modified mice were developed that harbour

mutations in human amyloid precursor protein associated with familial forms of AD (TgAPP) and that lead to age-dependent accumulation of amyloid. The study of these TgAPP models revealed that a prominent cerebrovascular dysfunction occurs prior to the onset of amyloid deposition, which would be consistent with impaired vasoreactivity and reduced CBF seen in AD patients [37]. TgAPP models are now being probed to study interactions with risk factors such as hypertension and high fat diet which in general have been shown to exacerbate the cerebrovascular dysfunction and progression of amyloid pathology [37,38].

Across the various models, vascular haemodynamics and NGVU coupling are impaired [see 28] and related to breakdown in cell-cell communication and signalling within the NGVU and supporting ECM. Whilst animal models are limited in their ability to fully recapitulate human SVD, they remain pertinent to tease out specific questions that are impossible to address in human studies and to identify molecular targets.

MECHANISMS RELEVANT TO CEREBRAL VASCULAR DISEASE

a) Endothelial-related mechanisms

The exact molecular and cellular mechanisms underlying cerebral microvascular disease remain elusive, but endothelial dysfunction seems to be especially important. Cerebral endothelial cells regulate vascular tone and blood flow, protect against thrombosis, inflammation and fibrosis, control exchange across the blood-brain barrier, modulate innate immunity and influence clearance of amyloid peptides [39,40]. In addition, and unique to the cerebrovascular system, the microvascular endothelium is critically involved in blood brain function and neuroprotection, through autoregulatory mechanisms that protect against barotrauma. Consequences of cerebrovascular autoregulatory dysfunction include structural injury to capillaries, microvascular rarefaction, exaggerated disruption of the blood brain barrier, neuroinflammation, neurodegeneration and increased susceptibility to intracerebral haemorrhage. This link between impaired autoregulation and downstream microvascular injury has been demonstrated experimentally and clinically.

Endothelial-cell (EC) signalling is mediated through production of numerous endothelial cell-derived vasoactive agents, including nitric oxide (NO), endothelium-derived hyperpolarizing factors (EDHF), endothelium-derived relaxing factors (EDRF), eicosanoid mediators (EETs, HETEs), prostaglandins, and endothelin-1 (ET-1) [41,42]. Endothelial-derived NO is not only a potent vasodilator, but also inhibits platelet aggregation, inflammation, apoptosis, fibrosis and vascular smooth muscle cell proliferation as well as modulates mitochondrial function, neuronal metabolism and synaptic transmission [43]. Cerebrovascular endothelial cells possess reactive oxygen species (ROS)-generating enzymes, such as NADPH oxidases (Nox) and mitochondrial oxidases that produce superoxide and hydrogen peroxide, important in redox signalling and endothelial function [44,45]. Because the endothelium is in direct contact with blood flow, it 'senses' haemodynamic changes and adapts accordingly through production of EC-derived factors, such as NO, EDRF and prostacyclins to induce vasodilation and prevent vascular damage or ET-1 and 20-hydroxyeicosatetraenoic acid to promote vasoconstriction. At the capillary level, endothelial cells are in direct contact with neurons via astrocytes and as such there is

‘cross-talk’ between vascular and neural cells through NGVU coupling, important in regulating neural activity and cerebral function [46].

Ageing, cardiovascular disease and ischaemia/hypoxia are associated with endothelial damage that impacts microvascular function, moment-to-moment adjustment of regional blood flow and neuronal function [47]. Molecular mechanisms involved include reduced microvascular eNOS-derived NO production with consequent decline in cerebrovascular, neuronal, astrocyte, microglial and angiogenic function. Mitochondrial damage, production of arachidonic metabolites and increased oxidative stress are also important. Decreased NO bioavailability in microvascular endothelial cells increases expression of amyloid precursor protein (A β PP) and β -site A β PP cleaving enzyme 1 (BACE-1) as well as A β formation, suggesting a role for endothelial dysfunction in neurodegenerative pathologies, such as Alzheimer’s disease [48,49]. Moreover chronic reduction of NO generation and increased production of pro-inflammatory cytokines (TNF- α , IL-1 β , interferon γ) increases endothelial permeability, transmigration of pro-inflammatory cells and blood brain barrier dysfunction, promoting neuroinflammatory and neurodegenerative processes [50,51].

Increased ROS production in the cerebral microvasculature is due primarily to hyperactivation of Noxs (particularly Nox2 and Nox4) [52–54], but also to disruption of mitochondrial respiratory chain oxidases, decreased anti-oxidant capacity, reduced nuclear factor erythroid 2–related factor 2 (Nrf-2) activity, uncoupled eNOS, and increased levels of asymmetric dimethylarginine (ADMA), an endogenous NOS inhibitor [55,56]. Vascular oxidative stress, activation of endothelial cell cation channels, such as transient receptor potential (TRP) melastatin 2 [57] and TRP vanilloid 4 cation channels [58], and induction of calcium and redox-sensitive signalling pathways promote oxidative modification of lipids, proteins and DNA causing endothelial, pericyte and neuronal cell injury [59]. Overexpression of the anti-oxidant superoxide dismutase –1 rescues cerebral endothelial dysfunction associated with neurodegeneration [60], while resveratrol treatment improves cerebrovascular endothelial function, reduces Nox activity and rescues NVGU coupling in aged mice [61].

Thus, endothelium-mediated mechanisms of cerebro-microvascular dysfunction involve a complex network of factors and systems. There is important interplay between molecular and cellular elements that regulate cerebral blood flow, blood brain function and the microvascular endothelium. Perturbations of these interconnections promote cerebral hypoperfusion, blood brain barrier damage and endothelial dysfunction, with consequent neurodegeneration and clinical manifestations of cognitive decline and vascular dementia. To date there are still no therapies to target the microvascular endothelium and hence management of these patients remains sub-optimal.

b) White matter, inflammation and hypoxia

Demyelinating lesions in the CNS white matter are a feature common to both small vessel disease (SVD) and multiple sclerosis (MS). MS has been studied in much greater detail than SVD, raising the possibility that knowledge gained in MS may help in understanding the demyelination in SVD. Demyelinating MS lesions have been classified into four types depending on their morphological features during lesion development [62]. Two types,

Patterns I and II, have morphological features consistent with an autoimmune aetiology, but a third type, Pattern III, has features suggesting an important role for tissue hypoxia, based on the similarity with demyelination in the penumbra around ischaemic foci. Since demyelination in SVD is likely to involve tissue hypoxia, it may be instructive to consider the factors determining the formation of Pattern III lesions in MS.

Our understanding of Pattern III demyelination has been greatly advanced by the introduction of a model lesion formed in the rodent spinal white matter by the direct intraspinal injection of the pro-inflammatory agent lipopolysaccharide (LPS) [63]. The lesion has been validated as an accurate model for Pattern III lesions in MS [62], and it results from innate, rather than autoimmune, mechanisms [65]. A surprising feature of the experimental Pattern III lesion is its location, because it does not form precisely at the site of injection (in this case in the middle of the dorsal columns), as is usual for demyelinating agents, [66,67] but rather it forms near the base of the dorsal columns, and after a delay of 7–10 days from the time of injection [68]. It is as if the LPS does not directly cause the demyelination, but rather sets in motion a train of events that culminates in the lesion forming at a nearby site. This peculiarity focusses attention on the features at the base of the dorsal columns that make it vulnerable, and these include a paucity of blood vessels, and location at a watershed between three arterial trees formed by long, fine, end arteries. All these features render the site particularly vulnerable to hypoxia, especially if the blood supply is impaired. The hypoxia kills the most vulnerable cells first, and these include the oligodendrocytes, resulting in the demyelination observed. The suspected key role of tissue hypoxia in causing Pattern III demyelination has been confirmed by the observation that breathing raised oxygen avoids tissue hypoxia, and prevents the demyelination [68].

In summary, impaired vascular perfusion, as occurs in cerebral SVD and MS, appears to cause tissue hypoxia that is most severe at sites rendered vulnerable by the vascular architecture, notably at poorly vascularised sites located at vascular watersheds, such as those in the periventricular white matter. The most vulnerable cells, oligodendrocytes, die first, resulting in demyelination, but the tissue can be protected from demyelination, in rodents, if hypoxia is avoided by breathing air enriched with oxygen.

c) Microvascular extracellular matrix and small vessels diseases of the brain.

The extracellular matrix (ECM) of cerebral blood vessels, and especially the basement membrane, is a key component of the NGVU that occupies a very strategic location, at the interface between the cerebral microcirculation and astrocytes [35]. Proteins constituting or associated with the ECM, referred to as “the matrisome”, have not only structural but also biochemical and signaling roles [69]. Hence, any change in the microvascular matrisome could have profound impact on the brain parenchyma. A common feature in both monogenic and sporadic forms of SVDs of the brain is the presence of major remodeling of the brain microvascular ECM, with prominent fibrosis, associated with severe degeneration of vascular smooth muscle cells [35]. Over the past ten years, genetic studies have revealed that most monogenic forms of SVDs are caused by mutations in genes encoding matrisome proteins, namely dominant mutations in the coding region of $\alpha 1$ (COL4A1) or $\alpha 2$ (COL4A2) chains of collagen type IV, a major component of vascular basement membranes,

in COL4A1/COL4A2-related hemorrhagic stroke [70,71], dominant gain-of-function mutations in the 3'UTR of COL4A1 in Pontine Autosomal Dominant Microangiopathy with Leukoencephalopathy (PADMAL) [72], recessive or dominant loss-of-function mutations in HTRA1, a serine protease regulating the TGF β pathway, in Cerebral Autosomal Recessive Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CARASIL) and HTRA1-related SVDs respectively [73–75], and dominant mutation in Cathepsin A in Cathepsin A-related arteriopathy with strokes and leukoencephalopathy (CARASAL) [76]. Moreover, recent work established that cerebrovascular manifestations of CADASIL, the most frequent hereditary SVD and the most aggressive vasculopathy, are driven by perturbations of the microvascular matrisome, as a consequence of an abnormal accumulation of the extracellular domain of Notch3 receptor [77,78]. Specifically, elevated levels of tissue inhibitor of metalloproteinases 3 (TIMP3), an ECM regulator, blunts the activity of the ADAM17/HB-EGF/(ErbB1/ErbB4) pathway leading to the upregulation of voltage-gated potassium channels subfamily 1 in cerebral arterial myocytes, thereby attenuating myogenic responses in brain arteries and compromising cerebral blood flow regulation in CADASIL [79].

Yet, much work remains to be done to understand in detail the mechanisms linking perturbations of the microvascular ECM and cerebrovascular manifestations in these hereditary SVDs. Remarkably, these recent findings suggest that similar mechanisms may be at work in sporadic SVDs. Therefore, work is needed to characterize the 'prefibrotic/transitional changes' of the brain microvascular matrisome in response to age or hypertension, two major risk factors of sporadic SVDs, and investigate their contribution to disease initiation. Also, with respect to fibrosis of small vessels in the brain, major gaps remain in our understanding of the mechanisms initiating the fibrosis response, in identifying the molecular and cellular mediators as well as the effector cells, and in understanding the relationship with SMC degeneration. Improvement of animal models of SVDs are needed to address these gaps.

d) Intramural periarterial drainage pathways

Arteries that supply the brain are vital for cerebral blood flow but they also play a major role in the drainage of interstitial fluid (ISF) from the brain. As arteries penetrate the brain from the subarachnoid space, they acquire a layer of pia mater that separates the arterial wall from the glia limitans. After injections of particulate and soluble tracers into the subarachnoid space, tracers are entering by glymphatic/convective influx within the arterial pial-glial basement membranes of cortical arteries [80]. When soluble fluorescent tracers are injected into the brain parenchyma, they rapidly drain out of the brain with ISF along basement membranes in the walls of cerebral capillaries and basement membranes surrounding smooth muscle cells of arteries, a process named intramural periarterial drainage (IPAD) [81]. Changes in arterial basement membranes related to genotype (apolipoprotein E4), age, or blockage due to immune complexes lead to a failure of intramural perivascular drainage pathways [82,83]. A recent study on a canine brain using electron microscopy demonstrated that all arterioles are enveloped in one complete layer of leptomeningeal cells, often with a second incomplete layer in the white matter, whereas venules in the white matter only occasionally possessed one layer only of leptomeningeal cells [84]. It is possible that dilated

perivascular spaces observed in the white matter are created between the two adventitial layers of pia mater as a result of the blocked drainage pathways in the overlying grey matter [85]. The extensive fibrosis and hyaline change seen in small vessel disease disrupts not only the basement membrane pathways carrying ISF out of the brain parenchyma but is also likely to contribute to the stiffening of the artery walls that would also impair drainage of ISF from cerebral white matter. Clarifying the key factors involved in the impairment of perivascular drainage of ISF such as the role of vascular smooth muscle cells and modulators of extracellular matrix are essential therapeutic strategies. It is currently unknown whether there is a pattern of anatomical or topographical changes in the cerebrovascular basement membrane and perivascular compartment architecture in brains susceptible to different degrees or subtypes of vascular dementia.

e) **The glymphatic fluid transport system (and interactions with amyloid)**

Lymphatic circulation is essential in peripheral organs for the removal of excess fluid and metabolic waste products; but the brain, in spite of having the highest metabolic activity of all tissues, has no conventional lymphatic system. A fundamentally novel pathway for fluid transport has recently been identified: the glymphatic system consisting of a periarterial cerebrospinal fluid (CSF) influx path and a perivenous interstitial fluid (ISF) clearance route, which are coupled through convective interstitial bulk flow supported by astrocytic AQP4 water channels [86]. It is designated the “glymphatic system” because it operates analogously to the peripheral lymphatic system and the CSF/ISF fluxes depend on astroglial AQP4 channels [87]. This brain-wide pathway serves as a waste disposal system of fluid, as well as larger solutes and proteins, such as amyloid and tau, from the CNS. Recent work has extended the glymphatic concept to show that outflow occurs along both cervical and meningeal/pial lymphatic vessels [88,89]. An interesting observation is that the sleep-wake cycle regulates glymphatic activity, which is primarily active during sleep, or the use of some anesthetic agents [90]. Glymphatic drainage is similar to lymphatic depending upon position, and the lateral and supine positions, which are the most popular sleep positions among human and most animal species, appear to be superior for amyloid-beta clearance compared with the prone position [91]. Ageing is linked to a sharp decline in glymphatic activity in wildtype mice [92]. Moreover, APP/PS1 mice – a murine model of AD exhibited reduced glymphatic activity in young mice without amyloid plaques as well as in older mice with plaques. Mice with multiple mini-strokes induced by intracarotid injection of cholesterol crystals similarly showed a global decrease in glymphatic function [93]. Also, traumatic brain injury triggered a sustained suppression of glymphatic activity [94], whereas middle-aged rats with diabetes exhibit increased influx, but reduced clearance, of contrast agents in an MRI study [95]. The latter observation can best be explained by trapping of the contrast agent within the neuropil due to pathological changes in the extracellular matrix and reactive gliosis, since the volume of fluid influx and efflux must match each other. Very recent small studies, one with Gadolinium injected into the CSF, the other using a novel MR technique (MREG), provided interesting evidence for the existence of glymphatic fluid transport in the human brain [96,97]. Altogether, glymphatic function has been shown to be altered in all disease states studied so far.

GAPS IN KNOWLEDGE AND REQUIREMENTS TO ADVANCE KNOWLEDGE

Following the focussed lectures the participants assembled in small groups and discussed the gaps in the different research areas and opportunities for development which are summarised in Table 1. There were several key themes to emerge from the discussion groups which are highlighted.

METHODOLOGICAL APPROACHES

a) Modelling the neurogliovascular unit in vitro

The neurogliovascular unit (NGVU) is arguably the most elementary representative functional unit of the brain and specific alterations in the NGVU underpin much of the pathophysiology of cerebrovascular disease. The ideal in-vitro model will depend upon the particular use and research question to be addressed. However, to probe disease mechanisms, attempts should be made to recapitulate the complex micro-environment of the NGVU, including the key cell types and the extracellular matrix. The constituent cells should also display mature properties of the NGVU such as the specialisation of endothelial cells to impart effective BBB function, specific transport mechanisms and the requisite cell-cell interactions including those that underpin NGVU coupling. NGVU models should be robust, yield reproducible results and be scalable if they are to be incorporated into drug screening programs. Current models can be broadly divided into easily adopted static compartment models such as Transwell cultures and more sophisticated flow models based upon a microfluidic design [98]. The latter have emerged in recognition of the importance of flow and shear stress of maintaining NGVU properties.

More than 80% of drug candidates tested in animal models for stroke, and a large proportion so far of drugs tested for AD, have failed in clinical trials. Better in-vitro mimics of human systems might help increase the likelihood of successful drug discovery. Notably there have been few trials to date of any drugs for SVD, therefore it would be premature to level the same criticism at human microvascular disease. Nonetheless, human stem cell technologies offer the opportunity to generate patient specific NGVU unit models for improved drug discovery and personalized medicine [99]. Differentiation protocols have been described that would produce all the constituent cells of the NGVU [100–102]. However further work is required to demonstrate the reproducibility of these methods and the ideal co-culture conditions.

NGVU in vitro models should enable assessment of physiological and pathophysiological mechanisms that would be difficult to dissect in vivo. Molecular ‘omics’ technologies in particular provide a means to evaluate disease processes in an unbiased approach and identify new drug targets. However, molecular studies require careful planning as they can be subject to significant technical confounds and non-relevant biological processes which are only beginning to be fully understood. Conducting studies with sufficient samples to allow data normalisation methods and remove nuisance variance is important. Single cell ‘omics’ are also a powerful technique to deal with heterogeneity in cell culture models as well as reveal cell-specific disease processes. These recent advances in tissue engineering,

stem cell methods and novel ‘omics’ platforms are anticipated to enable unprecedented mechanistic insights into NGVU brain disorders such as dementia [103].

b) Measuring behavioural outcomes in animal models

In human studies, different cognitive domains can be assessed with a battery of visual touchscreen-based tasks using similar stimuli and responses, thus facilitating between-task comparison and potentially reducing confounds [104–106]. Conversely, in the rodent, comprehensive cognitive batteries are seldom employed, and different cognitive domains are assessed by tasks that typically vary widely in the nature of stimuli, responses, reinforcers, and testing environment. Moreover, these tasks often bear no resemblance to the tests used with humans. Finally, the measurement of rodent behaviour is notoriously variable across labs and experimenters [107]. These factors reduce the likelihood of rodent and human studies assessing consistent and comparable cognitive functions, thus compromising the efficacy of translation. There is a recognised need to share standardised operating procedures for common outcomes and to improve translation.

One approach to addressing these issues is by using a touchscreen-based cognitive testing method for rodents, which has the potential to achieve more accurate, efficient, and reproducible phenotyping of rodents, and help bridge the translational divide between animal and human studies of cognition. This method uses an automated operant chamber with a computer monitor for the presentation of visual stimuli and an infrared touchscreen assembly to record the animal’s responses. The apparatus allows for the flexible presentation of visual stimuli at any location on the screen. Rats or mice respond directly to the stimuli by breaking the infrared beams overlaying the touchscreen with their nose. Appetitive reinforcers such as strawberry milkshake are delivered in a reward magazine to the rear of the chamber.

An extensive battery of tests using this touchscreen cognitive testing apparatus has been developed and validated. The tasks closely parallel human tests and have high translational face validity. Although face validity does not guarantee translational neurocognitive validity (i.e., the same cognitive constructs and circuits mediating the tasks across species), minimizing methodological differences enables back- and forward-translational opportunities and improves the likelihood of neurocognitive validity of touchscreen tasks [108–111]. Touchscreen-based tests now form a core component of recommended cognitive test batteries for models of schizophrenia (e.g., NEWMEDS and CNTRICS) and AD (e.g., PHARMACOG). The system is presented as a key method in the standard guide to behavioural testing for mouse researchers [112], and protocols for an extensive battery of tests have been published [113–115].

c) Experimental Design

Findings from in vivo research may be less reliable if those studies do not adopt and report measures to reduce the risk of bias in the experiments reported. The experimental stroke community have been at the forefront of implementing changes to improve the conduct and reporting of studies, but the recent impact of these efforts is not clear. A systematic identification of recent literature was conducted describing animal experiments inducing

middle cerebral artery occlusion or lacunar stroke, and text mining approaches developed automatically to ascertain risk of bias reporting from full text articles [116]. There were substantial improvements in the reporting of middle cerebral artery occlusion studies since the first systematic report in 2007 [117]. However, in reports of experiments in lacunar stroke there was no substantial improvement since the first systematic report of the field to 2012 [118]. This may in part reflect that there has been less work on SVD models. The accuracy (true positive plus true negative as a percentage of the total) of automated risk of bias annotation ranged from 67% (randomisation, lacunar stroke) to 100% (sample size calculation, middle cerebral artery occlusion). There therefore remains substantial opportunity for improvement in the reporting, and probably the conduct, of animal research modelling stroke, particularly lacunar stroke. Automated tools are sufficiently accurate to identify whether studies report the blinded assessment of outcome, but improvements are required in the tools to ascertain whether randomisation and a sample size calculation were reported.

d) Multi-centre pre-clinical studies

There are many steps in the translational pathway from original mechanistic discoveries through to successful translation of a therapy to the clinic. Progress in this pathway has been poor across a range of CNS diseases despite increased knowledge of the mechanistic basis of diseases, identification of drug targets and positive drug studies using in vitro and in vivo models. This failure to translate led to criticism of the quality of in vivo drug study design and reporting, and the publication and uptake of guidelines (e.g. STAIR, ARRIVE, RIGOR, IMPROVE) [119–123] to improve the translational potential of pre-clinical studies. However, single centre studies, although useful for proof of concept of a particular therapy, are unlikely to be rigorous enough to predict the therapies which will also be effective in man. What is needed is an additional step in the pathway where promising therapies which demonstrate efficacy in a number of single centre studies are then tested more rigorously on a multi-site platform. Multi-PART (Multicentre Preclinical Animal Research Team, <http://www.dcn.ed.ac.uk/multipart/>) is such a platform, set up with funding from EU FP7 for ischaemic stroke. However, the structure of the platform could easily be adapted for multi-site studies for any CNS disease.

The key objective of Multi-PART was “to implement and establish a platform for international multicentre preclinical stroke trials using the repertoire of randomised clinical trial design and the complexities of a multicentre, multimodel paradigm”. This was made possible by the experience within the Multi-PART team of scientists and clinicians with expertise in a range of stroke models and outcome measures, regulation and ethics of in vivo research, precision, reproducibility & external validity in animal research, design and running of clinical trials, statistics, database and web site management, good laboratory practice (GLP), and standard operating procedures (SOPs), development & costing structures etc. The design of the Multi-PART platform also benefitted from improvements in clinical trial design by incorporating strategies to minimize bias, biostatistical advances, data monitoring and auditing, etc.

Multicentre pre-clinical randomised control trials (pRCTs) in models relevant to SVD and VCI could be performed after single centre laboratory studies and a systematic review of all existing data, prior to clinical testing. The need for pRCTs reflects the repeated failure of translation from preclinical to clinical development and lack of reproducibility between laboratories. Since new healthcare interventions require one or more positive large multicentre clinical RCTs prior to introduction, pRCTs should largely follow the design of phase III clinical RCTs involving randomisation, treatment and outcome blinding [124–126]. Coordination would need a Trial Steering Committee and central database for management of randomisation and data storage. Outcomes would need central adjudication of imaging (e.g. MRI, histology for lesion volume, microbleeds) and videos (behavioural & functional testing). Studies can utilise advanced trial techniques such as adaptive design, randomisation, and statistical analysis, and the concept extended to designing observational and characterisation studies across multiple laboratories.

Key differences exist between preclinical and clinical RCTs, many of which could be ameliorated by adopting specific design elements in preclinical RCTs. Since patients are very heterogeneous, a variety of SVD models would be needed. Preclinical RCTs may need to incorporate both positive and neutral control comparator groups. Classically, trials have a single primary outcome but co-primary outcomes, composite outcomes, or statistical integration of several outcomes are alternatives that may be preferred. The Data Monitoring Committee will assess futility during the course of the study with the aim of stopping further development if data are not positive, thus preventing the need for further preclinical and clinical testing, and their considerable expense. Conversely, a positive multicentre pRCT will considerably enhance the justification for proceeding to clinical development.

Changing the views of industry, funding agencies and grant reviewers may be necessary to overcome perceptions that pRCTs are incremental and not novel or ground-breaking. For large pRCTs, authorship should be discussed prior to commencing studies and presents a potential issue for many basic science academics where decisions on hiring, promotion and returns on the research excellence framework (REF) are taken on publications and author position.

e) Biomarkers

Biomarkers can give insights into pathogenesis and suggest potential drug-able targets. They can inform prognosis and be used to ‘enrich’ trial populations with participants who are most likely to have outcomes of interest such as progression to dementia. Biomarkers can be used as surrogate outcome measures for phase II intervention trials, to screen treatment prior to large and expensive definitive phase 3 trials. Finally, biomarkers can be used for diagnostics. In this regard researchers were mindful of the continued debate around the value of biomarkers in diagnosis of Alzheimer’s disease (AD) [127,128]. The necessary properties and performance characteristics of a biomarker will vary with the proposed purpose.

MRI modalities were regarded as offering the greatest utility as SVD biomarkers. A number of different MRI markers of SVD may represent useful markers of disease including recent small subcortical infarcts, lacunes, white matter hyperintensities, brain volume, and white matter ultrastructure estimated on diffusion tensor imaging (DTI) or other quantitative

methods [129,130]. Increasingly sophisticated approaches to MRI are moving beyond gross anatomy to assess function and connectivity using approaches such as network analysis and these show promise in the mouse pre-clinical hypoperfusion model to predict outcome [131] but need further evaluation in prospective patient cohorts [132]. Computerised Tomography (CT) has value, particularly as it is routinely available but lacks sensitivity to early SVD change. For imaging, there is no suitable SVD target for radiolabelling that is analogous to amyloid imaging although PET approaches may be useful to assess parts of the pathophysiological process such as neuroinflammation. For tissue based markers, use of cerebrospinal fluid (CSF) is under-researched in SVD in direct contrast to its importance in AD. However, the dynamics of the exchange between the peptides in the interstitial fluid of the brain and the CSF and their routes in the perivascular compartment still require investigation. To date no blood based biomarker has shown utility, although with 'omics' based technologies new markers may be discovered. Electroencephalogram (EEG) has a role in certain neurodegenerative diseases but has limited application in SVD.

External validation, replication and standardisation of putative biomarkers is critical particularly for multicentre work. At present there is no SVD biomarker suitable for clinical use. Future trials and observational cohorts should create biobanks of tissue (blood, CSF) and imaging data that can be interrogated to validate existing biomarkers or discover potential new markers. If biomarkers are to be used as reliable surrogate markers in clinical trials, they must fulfil the following criteria: (1) they must be able to predict clinical outcome, as changes induced by a therapy on a surrogate marker are expected to reflect changes in a clinically meaningful end point; (2) change in a surrogate marker must be detectable prospectively; and (3) the sample size required to show therapeutic efficacy should be feasible in the setting of a clinical trial [133].

f) Sharing, model exchange and potential tissue banks

There is a growing need to address standardisation across models, as far as this is possible. This could include standardised protocols for surgery, behavioural testing and clearly defined genetic details in relation to models. Central facilities for provision of genetically modified mice would reduce the genetic drift inherent in many of the frequently used models. However, their utility is dependent on phenotypes. Human tissue banks are well established and provide a useful source of translational material. The development of a tissue bank for preclinical models may be a useful resource which could range from cut sections of tissues through to whole organs with standardisation of pathological approaches. Potential issues in relation to animal licensing (eg UK Home office) is acknowledged. Tissue banks may facilitate validation of published work in a low cost way, by providing tissues prepared by one published group for laboratory studies to be undertaken by a second group in a remote laboratory. An open access resource where data could be deposited would be particularly useful for negative studies that may not otherwise be published.

INDUSTRY PERSPECTIVE ON THE WORKSHOP

Independent of the shape of future research efforts there are a number of critical areas that need to be kept in mind that will help facilitate drug discovery and reduce the overall level of

risk. Firstly, the generation of high quality targets/ pathways with strong supporting neuropathological, genetic, and/ or epidemiological data. This will require the generation and interrogation of well characterised cohorts, using best practices for data generation and sharing that can be found in other pre-competitive settings; these cohorts will be additionally important for longitudinal tracking of disease and the identification of potential biomarkers that can be used to make early Go/NoGo decisions within drug development programs.

Secondly, there should be a strong focus on generating a robust translational pharmacology package to bridge between preclinical models and clinical development. A number of basic principles underpin this area: understand the temporal expression of target in both the model and the human disease; match the preclinical intervention paradigm to the intended therapeutic intent in the clinic (i.e. prevention versus treatment); demonstrate in preclinical studies drug exposure at the site of action/ target engagement, expression of downstream target pharmacology and importantly generate exposure-response relationships (e.g. EC50 values).

Finally, as far as possible standardise procedures/ protocols to reduce variability and improve reproducibility of preclinical studies. With this in mind the emergence of the EU-funded MultiPART initiative provides a network capability for the conduct of randomised preclinical studies in experimental models relevant to SVD. Together these approaches will all serve to “de-risk” clinical development and encourage further industry and academic investment in SVD research in dementia and stroke.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGEMENTS

A summary of the workshop proceedings consisting of short lectures and outcomes of discussion groups were provided by a writing group comprised of Joanna Wardlaw, Karen Horsburgh, Rhian Touyz, Ken Smith, Anne Joutel, Roxana Carare, Maiken Nedergaard, Zameel Cader, Lisa Saksida, Malcolm Macleod, Mhairi Macrae, Andy Lockhart, Philip Bath, Terence Quinn, Colin Smith, Atticus Hainsworth, Tracy Farr, Lorraine Work, Seth Love, Steve Williams, Michael O’Sullivan, Rajesh Kaloria, Anna Williams, Cheryl Hawkes, Stuart Allan, Patrick Kehoe, Catherine Hall, Jason Berwick, Christopher McCabe, Colin Smith, Tom Van Agtmael, Hugh Markus.

The administrative support of Margaret Kinninmont at the BHF Cardiovascular Centre, Glasgow is gratefully appreciated. The participation of representatives from ARUK, (Rosa Sancho), Alzheimer’s Society (Claire De May), Stroke Association (Kate Holmes) and Portland Press (Claire Curtis) is also gratefully acknowledged. We would also like to acknowledge funding and support from ARUK, ARUK Scotland network, Alzheimer’s Society, BHF and BHF Cardiovascular centre, MRC-DPUK, the Royal Society Edinburgh, Stroke Association and Fondation Leducq that made the workshop possible. PB is Stroke Association Professor of Stroke Medicine, and is a NIHR Senior Investigator.

REFERENCES

1. Bailey EL, McCulloch J, Sudlow C and Wardlaw JM (2009) Potential animal models of lacunar stroke: a systematic review. *Stroke* 40, e451–e458. [PubMed: 19390080]
2. Hainsworth AH, Allan SM, Boltze J, Cunningham C, Farris C, Head E, Ihara M, Isaacs JD, Kaloria RN, Lesnik Oberstein SA, Moss MB, Nitzsche B, Rosenberg GA, Rutten JW, Salkovic-Petrisic M, Troen AM. (2017) Translational models for vascular cognitive impairment: a review including larger species. *BMC Med.* 25;15(1):16. [PubMed: 28118831]

3. Wardlaw JM, Smith EE, Biessels GJ et al. (2013) Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration: a united approach. *Lancet Neurol* 12, 822–838. [PubMed: 23867200]
4. Esiri MM, Wilcock GK, Morris JH. (1997) Neuropathological assessment of the lesions of significance in vascular dementia. *J Neurol Neurosurg Psychiatry*. 63(6):749–53. [PubMed: 9416809]
5. Arvanitakis Z, Capuano AW, Leurgans SE, Bennett DA, Schneider JA. (2016) Relation of cerebral vessel disease to Alzheimer's disease dementia and cognitive function in elderly people: a cross-sectional study. *Lancet Neurol*. 15(9):934–943. [PubMed: 27312738]
6. Wardlaw JM, Allerhand M, Doubal FN et al. (2014) Vascular risk factors, large artery atheroma and brain white matter hyperintensities. *Neurology* 82, 1331–1338. [PubMed: 24623838]
7. Backhouse EV, McHutchison CA, Cvorov V, Shenkin SD and Wardlaw JM (2017) Early life risk factors for cerebrovascular disease: A systematic review and meta-analysis. *Neurology* 88(10):976–984. doi: 10.1212/WNL.0000000000003687. [PubMed: 28188307]
8. Wardlaw JM, Smith C and Dichgans M (2013) Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging. *Lancet Neurol* 12, 483–497. [PubMed: 23602162]
9. Shi Y, Thrippleton MJ, Makin SD, Marshall I, Geerlings MI, de Craen AJ, van Buchem MA, Wardlaw JM. (2016) Cerebral blood flow in small vessel disease: A systematic review and meta-analysis. *J Cereb Blood Flow Metab*. 36(10):1653–1667. [PubMed: 27496552]
10. Nylander R, Fahlström M, Rostrup E, Kullberg J, Damangir S, Ahlström H, Lind L, Larsson EM. (2017) Quantitative and qualitative MRI evaluation of cerebral small vessel disease in an elderly population: a longitudinal study. *Acta Radiol*. 284185117727567. doi: 10.1177/0284185117727567.
11. Haffner C, Malik R and Dichgans M (2016) Genetic factors in cerebral small vessel disease and their impact on stroke and dementia. *J Cereb Blood Flow Metab* 36, 158–171. [PubMed: 25899296]
12. Chappell F, Valdes Hernandez M, Makin S et al. (2017) Sample size considerations for trials using cerebral white matter hyperintensity progression as an intermediate outcome at 1 year after mild stroke: results from a prospective cohort study. *Trials* 18:78. [PubMed: 28222778]
13. METACOHORTS Consortium, Dichgans M, Wardlaw J and Smith E (2016) METACOHORTS for the study of vascular disease and its contribution to cognitive decline and neurodegeneration. An initiative of the Joint Programme for Neurodegenerative Disease research. *Alzheimers Dement* 12, 1235–1249. [PubMed: 27490018]
14. Potter GM, Doubal FN, Jackson CA et al. (2010) Counting cavitating lacunes underestimates the burden of lacunar infarction. *Stroke* 41, 267–272. [PubMed: 20044528]
15. Wardlaw JM, Chappell FM, Valdés Hernández MC, Makin SD, Staals J, Shuler K, Thrippleton MJ, Armitage PA, Muñoz-Maniega S, Heye AK, Sakka E, Dennis MS. (2017) White matter hyperintensity reduction and outcomes after minor stroke. *Neurology* 89:1003–1010. [PubMed: 28794252]
16. van Leijssen EMC, van Uden IWM, Ghafoorian M, Bergkamp MI, Lohner V, Kooijmans ECM, van der Holst HM, Tuladhar AM, Norris DG, van Dijk EJ, Rutten-Jacobs LCA, Platel B, Klijn CJM, de Leeuw F-E. (2017) Non-linear temporal dynamics of cerebral small vessel disease. The RUN DMC study. *Neurology* 89:1569–1577 [PubMed: 28878046]
17. Jessen NA, Munk AS, Lundgaard I and Nedergaard M (2015) The glymphatic system: a beginner's guide. *Neurochem Res* 40, 2583–2599. [PubMed: 25947369]
18. Lopez L, Hill WD, Harris SE et al. (2015) Genes from a translational analysis support a multifactorial nature of white matter hyperintensities. *Stroke* 46, 341–347. [PubMed: 25586835]
19. Jiwa NS, Garrard P, Hainsworth AH. (2010) Experimental models of vascular dementia and vascular cognitive impairment: a systematic review. *J Neurochem*. 115(4):814–28. [PubMed: 20731763]
20. Bailey EL, Smith C, Sudlow CL, Wardlaw JM. (2011) Is the spontaneously hypertensive stroke prone rat a pertinent model of sub cortical ischemic stroke? A systematic review. *Int J Stroke*. 6(5): 434–44. [PubMed: 21951409]

21. Ogata J, Fujishima M, Tamaki K, Nakatomi Y, Ishitsuka T, Omae T. (1981) Vascular changes underlying cerebral lesions in stroke-prone spontaneously hypertensive rats. A serial section study. *Acta Neuropathol.* 54(3):183–8. [PubMed: 7257727]
22. Bailey EL, McBride MW, Beattie W, McClure JD, Graham D, Dominiczak AF, Sudlow CL, Smith C, Wardlaw JM. (2014) Differential gene expression in multiple neurological, inflammatory and connective tissue pathways in a spontaneous model of human small vessel stroke. *Neuropathol Appl Neurobiol.* 19]40(7):855–72. [PubMed: 24417612]
23. Bailey EL, Wardlaw JM, Graham D, Dominiczak AF, Sudlow CL, Smith C. (2011) Cerebral small vessel endothelial structural changes predate hypertension in stroke-prone spontaneously hypertensive rats: a blinded, controlled immunohistochemical study of 5- to 21-week-old rats. *Neuropathol Appl Neurobiol.* 37(7):711–26. [PubMed: 21392049]
24. Brittain JF, McCabe C, Khatun H, Kaushal N, Bridges LR, Holmes WM, Barrick TR, Graham D, Dominiczak AF, Mhairi Macrae I, Hainsworth AH. (2013) An MRI-histological study of white matter in stroke-free SHRSP. *J Cereb Blood Flow Metab.* 33(5):760–3. [PubMed: 23403376]
25. Holland PR, Pannozzo MA, Bastin ME, McNeilly AD, Ferguson KJ, Caughey S, Jansen MA, Merrifield GD, Marshall I, Mullins JJ, Wardlaw JM, Sutherland C, Horsburgh K. (2015) Hypertension fails to disrupt white matter integrity in young or aged Fisher (F44) Cyp1a1Ren2 transgenic rats. *J Cereb Blood Flow Metab.* 35(2):188–92. [PubMed: 25407269]
26. Jalal FY, Yang Y, Thompson JF, Roitbak T, Rosenberg GA. (2015) Hypoxia-induced neuroinflammatory white-matter injury reduced by minocycline in SHR/SP. *J Cereb Blood Flow Metab.* 35(7):1145–53. [PubMed: 25712499]
27. Capone C, Faraco G, Park L, Cao X, Davisson RL, Iadecola C. (2011) The cerebrovascular dysfunction induced by slow pressor doses of angiotensin II precedes the development of hypertension. *Am J Physiol Heart Circ Physiol.* 300:H397–H407 [PubMed: 20971763]
28. Meissner A, Minnerup J, Soria G, Planas AM. (2017) Structural and functional brain alterations in a murine model of Angiotensin II-induced hypertension. *J Neurochem.* 140(3):509–521. [PubMed: 27874975]
29. Duncombe J, Kitamura A, Hase Y, Ihara M, Kalaria RN, Horsburgh K. (2017) Chronic cerebral hypoperfusion: a key mechanism leading to vascular cognitive impairment and dementia (VCID) Closing the translational gap between rodent models and human VCID. *Clin Sci (Lond)* 131(19): 2451–2468 [PubMed: 28963120]
30. Shibata M, Ohtani R, Ihara M, Tomimoto H, (2004) White matter lesions and glial activation in a novel mouse model of chronic cerebral hypoperfusion. *Stroke* 35(11), 2598–2603. [PubMed: 15472111]
31. Hattori Y, Enmi J, Iguchi S, Saito S, Yamamoto Y, Tsuji M et al. (2016) Gradual Carotid Artery Stenosis in Mice Closely Replicates Hypoperfusive Vascular Dementia in Humans. *J Am Heart Assoc* 5:e002757.
32. Coltman R, Spain A, Tsenkina Y, Fowler JH, Smith J, Allerhand M, Scott F, Kalaria RN, Ihara M, Dumas S, Deary IJ, Wood E, McCulloch J, Horsburgh K. (2011) Spatial memory in mice remains intact despite widespread white matter pathology *Neurobiol Aging* 32(12):2324.e7–2324.e12.
33. Holland PR, Searcy JL, Salvadores N, Scullion G, Chen G, Lawson G, Scott F, Bastin ME, Ihara M, Kalaria R, Wood ER, Smith C, Wardlaw JM, Horsburgh K. (2015) Gliovascular disruption and cognitive deficits in a mouse model with features of small vessel disease. *J Cereb Blood Flow Metab.* 35(6):1005–14 [PubMed: 25669904]
34. Wardlaw JM, Allerhand M, Eadie E, Thomas A, Corley J, Pattie A, Taylor A, Shenkin SD, Cox S, Gow A, Starr JM, Deary IJ. (2017) Carotid disease at age 73 and cognitive change from age 70 to 76 years: A longitudinal cohort study. *J Cereb Blood Flow Metab.* 37(8):3042–3052 [PubMed: 28155579]
35. Joutel A, Haddad I, Ratelade J, Nelson MT. (2016) Perturbations of the cerebrovascular matrisome: A convergent mechanism in small vessel disease of the brain? *J Cereb Blood Flow Metab.* 36(1): 143–57. [PubMed: 25853907]
36. Rannikmäe K et al. Van Agtmael T, Woo D, Markus HS, Seshadri S, Rosand J, Sudlow CL (2015) Common variation in COL4A1/COL4A2 is associated with sporadic cerebral small vessel disease. *Neurology* 84, 918–26 [PubMed: 25653287]

37. Iadecola C (2013) The pathobiology of vascular dementia. *Neuron*. 80(4):844–66. [PubMed: 24267647]
38. Salvadores N, Searcy JL, Holland PR, Horsburgh K. (2017) Chronic cerebral hypoperfusion alters amyloid- β peptide pools leading to cerebral amyloid angiopathy, microinfarcts and hemorrhages in Tg-SwDI mice. *Clin Sci (Lond)*. 131(16):2109–2123 [PubMed: 28667120]
39. Lyros E, Bakogiannis C, Liu Y, Fassbender K. (2014) Molecular links between endothelial dysfunction and neurodegeneration in Alzheimer's disease. *Curr Alzheimer Res*. 11(1):18–26 [PubMed: 24251393]
40. Bell RD, Winkler EA, Sagare AP, Singh I, LaRue B, Deane R, Zlokovic BV. (2010) Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. *Neuron*. 68(3):409–27. [PubMed: 21040844]
41. Katusic ZS, Austin SA. (2014) Endothelial nitric oxide: protector of a healthy mind. *Eur Heart J*. 35(14):888–894. [PubMed: 24357508]
42. Faraci FM. (2011) Protecting against vascular disease in brain. *Am J Physiol Heart Circ Physiol*. 300(5):H1566–158 [PubMed: 21335467]
43. Busija DW, Rutkai I, Dutta S, Katakam PV. (2016) Role of Mitochondria in Cerebral Vascular Function: Energy Production, Cellular Protection, and Regulation of Vascular Tone. *Compr Physiol*. 6(3):1529–48 [PubMed: 27347901]
44. Yanagida K, Liu CH, Faraco G, Galvani S, Smith HK, Burg N, Anrather J, Sanchez T, Iadecola C, Hla T. (2017) Size-selective opening of the blood-brain barrier by targeting endothelial sphingosine 1-phosphate receptor 1. *Proc Natl Acad Sci U S A*. 114(17):4531–4536 [PubMed: 28396408]
45. Chrissobolis S, Banfi B, Sobey CG, Faraci FM. (2012) Role of Nox isoforms in angiotensin II-induced oxidative stress and endothelial dysfunction in brain. *J Appl Physiol*. 113(2):184–91 [PubMed: 22628375]
46. Lourenço CF, Ledo A, Barbosa RM, Laranjinha J. (2017) Neurovascular-neuroenergetic coupling axis in the brain: master regulation by nitric oxide and consequences in aging and neurodegeneration. *Free Radic Biol Med*. pii: S0891–5849(17)30229–0
47. de la Torre JC. (2012) Cerebral hemodynamics and vascular risk factors: setting the stage for Alzheimer's disease. *J Alzheimers Dis*. 32(3):553–567 [PubMed: 22842871]
48. Merlini M, Shi Y, Keller S, Savarese G, Akhmedov A, Derungs R, Spescha RD, Kulic L, Nitsch RM, Lüscher TF, Camici GG. Reduced nitric oxide bioavailability mediates cerebroarterial dysfunction independent of cerebral amyloid angiopathy in a mouse model of Alzheimer's disease. *Am J Physiol Heart Circ Physiol*. 2017;312(2):H232–H238 [PubMed: 27836896]
49. Koizumi K, Wang G, Park L. Endothelial Dysfunction and Amyloid- β -Induced Neurovascular Alterations. *Cell Mol Neurobiol*. 2016;36(2):155–65 [PubMed: 26328781]
50. Basuroy S, Bhattacharya S, Leffler CW, Parfenova H. (2009) Nox4 NADPH oxidase mediates oxidative stress and apoptosis caused by TNF- α in cerebral vascular endothelial cells. *Am J Physiol Cell Physiol*. 296(3):C422–32 [PubMed: 19118162]
51. Matsumoto J, Takata F, Machida T, Takahashi H, Soejima Y, Funakoshi M, Futagami K, Yamauchi A, Dohgu S, Kataoka Y. (2014) Tumor necrosis factor- α -stimulated brain pericytes possess a unique cytokine and chemokine release profile and enhance microglial activation. *Neurosci Lett*. 578:133–8 [PubMed: 24993300]
52. Chrissobolis S, Drummond GR, Faraci FM, Sobey CG. (2014) Chronic aldosterone administration causes Nox2-mediated increases in reactive oxygen species production and endothelial dysfunction in the cerebral circulation. *J Hypertens*. 32(9):1815–21 [PubMed: 24991871]
53. Kuroda J, Ago T, Nishimura A, Nakamura K, Matsuo R, Wakisaka Y, Kamouchi M, Kitazono T. (2014) Nox4 is a major source of superoxide production in human brain pericytes. *J Vasc Res*. 51(6):429–38. [PubMed: 25612841]
54. Cahill-Smith S, Li JM. (2014) Oxidative stress, redox signalling and endothelial dysfunction in ageing-related neurodegenerative diseases: a role of NADPH oxidase 2. *Br J Clin Pharmacol*. 78(3):441–53. [PubMed: 25279404]
55. Ghosh N, Ghosh R, Mandal SC. (2011) Antioxidant protection: A promising therapeutic intervention in neurodegenerative disease. *Free Radic Res*. 45(8):888–905 [PubMed: 21615270]

56. Rodionov RN, Dayoub H, Lynch CM, Wilson KM, Stevens JW, Murry DJ, Kimoto M, Arning E, Bottiglieri T, Cooke JP, Baumbach GL, Faraci FM, Lentz SR. (2010) Overexpression of dimethylarginine dimethylaminohydrolase protects against cerebral vascular effects of hyperhomocysteinemia. *Circ Res.* 106(3):551–8 [PubMed: 20019334]
57. Park L, Wang G, Moore J, Girouard H, Zhou P, Anrather J, Iadecola C. (2014) The key role of transient receptor potential melastatin-2 channels in amyloid-beta-induced neurovascular dysfunction. *Nat Commun.* 5:5318–5320. [PubMed: 25351853]
58. Zhang L, Papadopoulos P, Hamel E. (2013) Endothelial TRPV4 channels mediate dilation of cerebral arteries: impairment and recovery in cerebrovascular pathologies related to Alzheimer's disease. *Br J Pharmacol.* 170(3):661–70. [PubMed: 23889563]
59. Shefa U, Yeo SG, Kim MS, Song IO, Jung J, Jeong NY, Huh Y. (2017) Role of Gasotransmitters in Oxidative Stresses, Neuroinflammation, and Neuronal Repair. *Biomed Res Int.* 1689341. doi: 10.1155/2017/1689341.
60. Iadecola C, Zhang F, Niwa K, Eckman C, Turner SK, Fischer E, Younkin S, Borchelt DR, Hsiao KK, Carlson GA. (1999) SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein. *Nat Neurosci.* 2(2):157–161. [PubMed: 10195200]
61. Toth P, Tarantini S, Tucsek Z, Ashpole NM, Sosnowska D, Gautam T, Ballabh P, Koller A, Sonntag WE, Csizsar A, Ungvari Z. (2014) Resveratrol treatment rescues neurovascular coupling in aged mice: role of improved cerebrovascular endothelial function and downregulation of NADPH oxidase. *Am J Physiol Heart Circ Physiol.* 306(3):H299–308. [PubMed: 24322615]
62. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, & Lassmann H (2000). Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. *Ann Neurol* 47, 707–717. [PubMed: 10852536]
63. Felts PA, Woolston AM, Fernando HB, Asquith S, Gregson NA, Mizzi OJ, & Smith KJ (2005). Inflammation and primary demyelination induced by the intraspinal injection of lipopolysaccharide. *Brain* 128, 1649–1666. [PubMed: 15872019]
64. Marik C, Felts PA, Bauer J, Lassmann H, & Smith KJ (2007). Lesion genesis in a subset of patients with multiple sclerosis: a role for innate immunity? *Brain* 130, 2800–2815. [PubMed: 17956913]
65. Sharma R, Fischer MT, Bauer J, Felts PA, Smith KJ, Misu T, Fujihara K, Bradl M, & Lassmann H (2010). Inflammation induced by innate immunity in the central nervous system leads to primary astrocyte dysfunction followed by demyelination. *Acta Neuropathologica* 120, 223–236. [PubMed: 20532539]
66. Smith KJ, Blakemore WF, & McDonald WI (1979). Central remyelination restores secure conduction. *Nature* 280, 395–396. [PubMed: 460414]
67. Smith KJ & Hall SM (1994). Central demyelination induced in vivo by the calcium ionophore ionomycin. *Brain* 117, 1351–1356. [PubMed: 7820571]
68. Desai RA, Davies AL, Tachrount M, Kasti M, Laulund F, Golay X, & Smith KJ (2016). Cause and prevention of demyelination in a model multiple sclerosis lesion. *Ann Neurol* 79, 591–604. [PubMed: 26814844]
69. Hynes RO, Naba A. (2012) Overview of the matrisome--an inventory of extracellular matrix constituents and functions. *Cold Spring Harb Perspect Biol.* 4:a004903.
70. Gould DB, Phalan FC, Breedveld GJ, van Mil SE, Smith RS, Schimenti JC, Aguglia U, van der Knaap MS, Heutink P, John SWM. (2005) Mutations in Col4a1 cause perinatal cerebral hemorrhage and porencephaly. *Science.* 308:1167–1171. [PubMed: 15905400]
71. Kuo DS, Labelle-Dumais C, Gould DB. (2012) COL4A1 and COL4A2 mutations and disease: insights into pathogenic mechanisms and potential therapeutic targets. *Hum Mol Genet.* 21(R1):R97–110. [PubMed: 22914737]
72. Verdura E, Hervé D, Bergametti F, Jacquet C, Morvan T, Prieto-Morin C, Mackowiak A, Manchon E, Hosseini H, Cordonnier C, Girard-Buttaz I, Rosenstingl S, Hagel C, Kuhlenbäumer G, Leca-Radu E, Goux D, Fleming L, Van Agtmael T, Chabriat H, Chapon F, Tournier-Lasserre E. (2016) Disruption of a miR-29 binding site leading to COL4A1 upregulation causes pontine autosomal dominant microangiopathy with leukoencephalopathy. *Ann Neurol.* 80:741–753. [PubMed: 27666438]

73. Hara K, Shiga A, Fukutake T, Nozaki H, Miyashita A, Yokoseki A, Kawata H, Koyama A, Arima K, Takahashi T, Ikeda M, Shiota H, Tamura M, Shimoe Y, Hirayama M, Arisato T, Yanagawa S, Tanaka A, Nakano I, Ikeda S, Yoshida Y, Yamamoto T, Ikeuchi T, Kuwano R, Nishizawa M, Tsuji S, Onodera O. (2009) Association of HTRA1 mutations and familial ischemic cerebral small-vessel disease. *N Engl J Med*. 360:1729–39. [PubMed: 19387015]
74. Beaufort N, Scharrer E, Kremmer E, Lux V, Ehrmann M, Huber R, Houlden H, Werring D, Haffner C, Dichgans M. (2014) Cerebral small vessel disease-related protease HtrA1 processes latent TGF- β binding protein 1 and facilitates TGF- β signaling. *Proc Natl Acad Sci USA*. 111:16496–16501. [PubMed: 25369932]
75. Verdura E, Hervé D, Scharrer E, Amador MDM, Guyant-Maréchal L, Philippi A, Corlobé A, Bergametti F, Gazal S, Prieto-Morin C, Beaufort N, Le Bail B, Viakhireva I, Dichgans M, Chabriat H, Haffner C, Tournier-Lasserre E. (2015) Heterozygous HTRA1 mutations are associated with autosomal dominant cerebral small vessel disease. *Brain*. 138:2347–2358. [PubMed: 26063658]
76. Bugiani M, Kevelam SH, Bakels HS, Waisfisz Q, Ceuterick-de Groote C, Niessen HWM, Abbink TEM, Lesnik Oberstein SAMJ, van der Knaap MS. (2016) Cathepsin A-related arteriopathy with strokes and leukoencephalopathy (CARASAL). *Neurology* 87:1777–1786. [PubMed: 27664989]
77. Monet-Leprêtre M, Haddad I, Baron-Menguy C, Fouillot-Panchal M, Riani M, Domenga-Denier V, Dussaule C, Cognat E, Vinh J, Joutel A. (2013) Abnormal recruitment of extracellular matrix proteins by excess Notch3 ECD: a new pathomechanism in CADASIL. *Brain* 136:1830–1845. [PubMed: 23649698]
78. Capone C, Cognat E, Ghezali L, Baron-Menguy C, Aubin D, Mesnard L, Stöhr H, Domenga-Denier V, Nelson MT, Joutel A. (2016) Reducing Timp3 or vitronectin ameliorates disease manifestations in CADASIL mice. *Ann Neurol*. 79:387–403. [PubMed: 26648042]
79. Capone C, Dabertrand F, Baron-Menguy C, Chalaris A, Ghezali L, Domenga-Denier V, Schmidt S, Huneau C, Rose-John S, Nelson MT, Joutel A. (2016) Mechanistic insights into a TIMP3-sensitive pathway constitutively engaged in the regulation of cerebral hemodynamics. *Elife* 5.
80. Morris AW, Sharp MM, Albargothy NJ, Fernandes R, Hawkes CA, Verma A, et al. (2016) Vascular basement membranes as pathways for the passage of fluid into and out of the brain. *Acta neuropathologica*. 131(5):725–36. doi: 10.1007/s00401-016-1555-z. [PubMed: 26975356]
81. Carare RO, Bernardes-Silva M, Newman TA, Page AM, Nicoll JA, Perry VH, et al. (2008) Solutes, but not cells, drain from the brain parenchyma along basement membranes of capillaries and arteries: significance for cerebral amyloid angiopathy and neuroimmunology. *NeuropatholApplNeurobiol*. 34(2):131–44.
82. Hawkes CA, Hartig W, Kacza J, Schliebs R, Weller RO, Nicoll JA, et al. (2011) Perivascular drainage of solutes is impaired in the ageing mouse brain and in the presence of cerebral amyloid angiopathy. *Acta neuropathologica*. 121(4):431–43. [PubMed: 21259015]
83. Hughes TM, Kuller LH, Barinas-Mitchell EJ, Mackey RH, McDade EM, Klunk WE, et al. (2013) Pulse wave velocity is associated with beta-amyloid deposition in the brains of very elderly adults. *Neurology*. 81(19):1711–8. [PubMed: 24132374]
84. Criswell TP, Sharp MM, Dobson H, Finucane C, Weller RO, Verma A, et al. (2017) The structure of the perivascular compartment in the old canine brain: a case study. *Clin Sci (Lond)*. 131(22): 2737–44. [PubMed: 28982724]
85. Kalaria RN. (2016) Neuropathological diagnosis of vascular cognitive impairment and vascular dementia with implications for Alzheimer's disease. *Acta neuropathologica*. 131(5):659–85. [PubMed: 27062261]
86. Iliff JJ et al. (2012) A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid beta. *Science translational medicine* 4, 147ra111, doi:10.1126/scitranslmed.3003748
87. Nedergaard M (2013) Neuroscience. Garbage truck of the brain. *Science* 340, 1529–1530, doi: 10.1126/science.1240514 [PubMed: 23812703]
88. Louveau A et al. (2015) Structural and functional features of central nervous system lymphatic vessels. *Nature* 523, 337–341, doi:10.1038/nature14432 [PubMed: 26030524]

89. Aspelund A et al. (2015) A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. *The Journal of experimental medicine* 212, 991–999, doi:10.1084/jem.20142290 [PubMed: 26077718]
90. Xie L et al. (2013) Sleep drives metabolite clearance from the adult brain. *Science* 342, 373–377, doi:10.1126/science.1241224 [PubMed: 24136970]
91. Lee H et al. (2015) the Effect of Body Posture on Brain Glymphatic Transport. *The Journal of neuroscience : the official journal of the Society for Neuroscience* 35, 11034–11044, doi:10.1523/JNEUROSCI.1625-15.2015 (2015).
92. Kress BT et al. (2014) Impairment of paravascular clearance pathways in the aging brain. *Annals of neurology*, doi:10.1002/ana.24271
93. Venkat P et al. (2017) White matter damage and glymphatic dysfunction in a model of vascular dementia in rats with no prior vascular pathologies. *Neurobiology of aging* 50, 96–106, doi: 10.1016/j.neurobiolaging.2016.11.002 [PubMed: 27940353]
94. Iliff JJ et al. (2014) Impairment of glymphatic pathway function promotes tau pathology after traumatic brain injury. *The Journal of neuroscience : the official journal of the Society for Neuroscience* 34, 16180–16193, doi:10.1523/JNEUROSCI.3020-14. [PubMed: 25471560]
95. Jiang Q et al. (2016) Impairment of the glymphatic system after diabetes. *Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism*, doi:10.1177/0271678X16654702
96. Eide PK & Ringstad G (2015) MRI with intrathecal MRI gadolinium contrast medium administration: a possible method to assess glymphatic function in human brain. *Acta radiologica open* 4, 2058460115609635, doi:10.1177/2058460115609635
97. Kiviniemi V et al. (2015) Ultra-fast magnetic resonance encephalography of physiological brain activity -Glymphatic pulsation mechanisms? *Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism*, doi: 10.1177/0271678X15622047
98. van der Meer AD, Orlova VV, ten Dijke P, van den Berg A and Mummery CL (2013) Three-dimensional co-cultures of human endothelial cells and embryonic stem cell-derived pericytes inside a microfluidic device. *Lab Chip*. 13, 3562–3568 [PubMed: 23702711]
99. Shi Y, Inoue H, Wu JC, Yamanaka S. (2017) Induced pluripotent stem cell technology: S decade of progress. *Nat Rev Drug Discov*. 16(2):115–130. [PubMed: 27980341]
100. Lippmann ES, Azarin SM, Kay JE, Nessler RA, Wilson HK, Al-Ahmad A, Palecek SP and Shusta EV (2012) Human Blood-Brain Barrier Endothelial Cells Derived from Pluripotent Stem Cells. *Nature Biotechnol*. 30, 783–791 [PubMed: 22729031]
101. Canfield SG, Stebbins MJ, Morales BS, Asai SW, Vatine GD, Svendsen CN, Palecek SP and Shusta EV (2017) An isogenic blood–brain barrier model comprising brain endothelial cells, astrocytes, and neurons derived from human induced pluripotent stem cells. *J. Neurochem*. 140, 874–888 [PubMed: 27935037]
102. Cheung C, Bernardo AS, Trotter MW, Pedersen RA, Sinha S. (2012) Generation of human vascular smooth muscle subtypes provides insight into embryological origin-dependent disease susceptibility. *Nat Biotechnol*. 30(2):165–73. [PubMed: 22252507]
103. Moffat JG, Vincent F, Lee JA, Eder J, Prunotto M.(2017) Opportunities and challenges in phenotypic drug discovery: an industry perspective. *Nat Rev Drug Discov*. 16(8):531–543. [PubMed: 28685762]
104. Sahakian BJ & Owen AM (1992) Computerized assessment in neuropsychiatry using CANTAB: discussion paper. *J R Soc Med* 85, 399–402 [PubMed: 1629849]
105. Levaux M-N et al. (2007) Computerized assessment of cognition in schizophrenia: promises and pitfalls of CANTAB. *Eur. Psychiatry* 22, 104–115 [PubMed: 17227707]
106. Barnett JH et al. (2010) Assessing cognitive function in clinical trials of schizophrenia. *Neurosci Biobehav Rev* 34, 1161–1177 [PubMed: 20105440]
107. Crabbe JC (1999) Genetics of Mouse Behavior: Interactions with Laboratory Environment. *Science* 284, 1670–1672 [PubMed: 10356397]

108. Romberg C, Mattson MP, Mughal MR, Bussey TJ & Saksida LM (2011) Impaired attention in the 3xTgAD mouse model of Alzheimer's disease: rescue by donepezil (Aricept). *Journal of Neuroscience* 31, 3500–3507 [PubMed: 21368062]
109. Nithianantharajah J & Grant SGN (2013) Cognitive components in mice and humans: Combining genetics and touchscreens for medical translation. *Neurobiol Learn Mem* doi:10.1016/j.nlm.2013.06.006
110. Nithianantharajah J et al. (2015) Bridging the translational divide: identical cognitive touchscreen testing in mice and humans carrying mutations in a disease-relevant homologous gene. *Nature Publishing Group* 5, 14613
111. Talpos J & Steckler T Touching on translation. *Cell Tissue Res.* 354, 297–308 (2013). [PubMed: 23949375]
112. Crawley JN What's Wrong With My Mouse? (John Wiley & Sons, 2007). doi: 10.1002/0470119055
113. Mar AC et al. The touchscreen operant platform for assessing executive function in rats and mice. *Nat Protoc* 8, 1985–2005 (2013). [PubMed: 24051960]
114. Horner AE et al. (2013) The touchscreen operant platform for testing learning and memory in rats and mice. *Nat Protoc* 8, 1961–1984 [PubMed: 24051959]
115. Oomen CA et al. (2013) The touchscreen operant platform for testing working memory and pattern separation in rats and mice. *Nat Protoc* 8, 2006–2021 [PubMed: 24051961]
116. Babor Z, Liao J, Macleod MR, Bannach-Brown A, McCann SK, Wever KE, Thomas J, Ottavi T, Howells DW, Rice A, Ananiadou S, Sena E.(2017) Risk of bias reporting in the recent animal focal cerebral ischaemia literature. *Clin Sci (Lond)*.131(20):2525–2532. doi: 10.1042/CS20160722. [PubMed: 29026002]
117. Sena E, van der Worp HB, Howells D, Macleod MR (2007) How can we improve the pre-clinical development of drugs for stroke? *Trends Neurosci.* 30, 433–439 [PubMed: 17765332]
118. Pedder H, Vesterinen HV, Macleod MR, Wardlaw JM(2014) Systematic review and meta-analysis of interventions tested in animal models of lacunar stroke. *Stroke* 45, 563–570 [PubMed: 24385271]
119. Stroke therapy academic industry roundtable (Chair Fisher M) (1999) Recommendations for standards regarding preclinical neuroprotective and restorative drug development. *Stroke.* 30:2752–2758. [PubMed: 10583007]
120. Fisher M, Feuerstein G, Howells DW, Hurn PD, Kent TA, Savitz SI, Lo EH; STAIR Group. (2009) Update of the stroke therapy academic industry roundtable preclinical recommendations. *Stroke.* 40(6):2244–50. doi: 10.1161/STROKEAHA.108.541128. [PubMed: 19246690]
121. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG (2010) Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research. *PLoS Biol.* 8, e1000412
122. RIGOR. Improving the quality of NINDS-supported preclinical and Clinical Research through rigorous study design and transparent reporting. 2012; Available from: http://www.ninds.nih.gov/funding/transparency_in_reporting_guidance.pdf
123. Percie du Sert N, Alfieri A, Allan SM, Carswell HV, Deuchar GA, Farr TD, Flecknell P, Gallagher L, Gibson CL, Haley MJ, Macleod MR, McColl BW, McCabe C, Morancho A, Moon LD, O'Neill MJ, Pérez de Puig I, Planas A, Ragan CI, Rosell A, Roy LA, Ryder KO, Simats A, Sena ES, Sutherland BA, Tricklebank MD, Trueman RC, Whitfield L, Wong R, Macrae IM. (2017) The IMPROVE Guidelines (Ischaemia Models: Procedural Refinements Of in Vivo Experiments). *J Cereb Blood Flow Metab.* 37(11):3488–3517. doi: 10.1177/0271678X17709185. [PubMed: 28797196]
124. Bath PM, Macleod MR, Green AR. (2009) Emulating multicentre clinical stroke trials: A new paradigm for studying novel interventions in experimental models of stroke. *Int J Stroke.* 4:471–479 [PubMed: 19930059]
125. Llovera G, Hofmann K, Roth S, Salas-Perdoma A, Ferrer-Ferrer M, Perego C, et al. (2015) Results of a preclinical randomized controlled multicentre trial (prct): Anti-cd49d treatment for acute brain ischemia. *Science Translational Medicine.* 7:299ra121

126. Maysami S, Wong R, Pradillo J, Denes A, Dhungana H, Malm T, et al. (2016) A cross-laboratory preclinical study on the effectiveness of interleukin-1 receptor antagonist in stroke. *Journal of Cerebral Blood Flow and Metabolism*. 36:596–605 [PubMed: 26661169]
127. Noel-Storr AH, Flicker L, Ritchie CW, Nguyen GH, Gupta T, Wood P, Walton J, Desai M, Solomon DF, Molena E, Worrall R, Hayen A, Choudhary P, Ladds E, Lanctôt KL, Verhey FR, McCleery JM, Mead GE, Clare L, Fioravanti M, Hyde C, Marcus S, McShane R. (2013) Systematic review of the body of evidence for the use of biomarkers in the diagnosis of dementia. *Alzheimers Dement*.9(3):e96–e105. doi: 10.1016/j.jalz.2012.01.014. [PubMed: 23110863]
128. Ritchie C, Smailagic N, Noel-Storr AH, Ukoumunne O, Ladds EC, Martin S.(2017) CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). *Cochrane Database Syst Rev*.3:CD010803. doi: 10.1002/14651858.CD010803.pub2.
129. Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, et al. (2013) Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. *Lancet Neurol* 12: 822–838. [PubMed: 23867200]
130. Lawrence AJ, Chung AW, Morris RG, Markus HS, Barrick TR. (2014) Structural network efficiency is associated with cognitive impairment in small-vessel disease. *Neurology* 83: 304–311. [PubMed: 24951477]
131. Boehm-Sturm P, Fächte-meier M, Foddis M, Mueller S, Trueman RC, Zille M, Rinnenthal JL, Kypraios T, Shaw L, Dirnagl U, Farr TD. (2017) Neuroimaging Biomarkers Predict Brain Structural Connectivity Change in a Mouse Model of Vascular Cognitive Impairment. *Stroke*. 48(2):468–475. doi: 10.1161/STROKEAHA.116.014394. [PubMed: 28070001]
132. Benjamin P, Zeestraten E, Lambert C, Ster IC, Williams OA, Lawrence AJ, Patel B, MacKinnon AD, Barrick TR, Markus HS. (2016) Progression of MRI markers in cerebral small vessel disease: Sample size considerations for clinical trials. *J Cereb Blood Flow Metab* 36:228–40. [PubMed: 26036939]
133. Quinn TJ, McCleery J. (2017) Diagnosis in vascular dementia, applying ‘Cochrane diagnosis rules’ to ‘dementia diagnostic tools’. *Clin Sci (Lond)*.131(8):729–732. doi: 10.1042/CS20170025. [PubMed: 28385828]




Figure 1: Mechanisms relevant to cerebral vascular disease.

An outline of mechanisms relevant to cerebral vascular disease and VCI. These mechanisms were highlighted during the workshop and described in more detail in the text. In general, downstream of risk factors, a cascade of key events are indicated, of which some may be considered as primary events (eg endothelial changes, inflammation, oxidative stress) and may also be bidirectional, leading to cognitive impairment. (Abbreviations: BBB, blood brain barrier, MMP, matrix metalloproteinase)

Gaps in knowledge and requirements to advance knowledge.

A summary of outcomes of discussion groups at the workshop are outlined in the table. Several key mechanisms, the gaps in knowledge and requirements for early advances in knowledge were highlighted. (Abbreviations: AD, Alzheimer's disease; BBB, blood brain barrier; CBF, cerebral blood flow; CSF, cerebrospinal fluid; DTI, Diffusion Tensor Imaging; EEG, electroencephalogram; ISF, interstitial fluid; MRI, Magnetic Resonance Imaging; MMP, matrix metalloproteinase; NVU, neurovascular unit; SVD, small vessel disease; TIMPs, tissue inhibitor of metalloproteinase; VCI, Vascular Cognitive Impairment; VaD, Vascular Dementia)

Table 1:

Mechanism	Gaps in knowledge	Requirements for early advances in knowledge
Common to all mechanisms	<ul style="list-style-type: none"> The most relevant model for human SVD is unclear Regional variation in CBF, in vulnerability to low flow, hypoxia or inflammation, and in flow-metabolism coupling, in grey and white matter (periventricular and deep), in normal tissue and in SVD, is not well established. Influence of regional differences (e.g. in arteriolar morphology between lenticulostriate and cortical perforating arterioles) in microvessel and perivascular structures on lesion development is poorly understood. 	<ul style="list-style-type: none"> Use different models to recapitulate components of SVD appropriate to the specific research question Better <i>in vitro</i> and <i>in vivo</i> models of BBB function and dysfunction, including under conditions of shear stress, in cell co-cultures (3D >2D) and including the glycoecalyx A reliable 'neuro-glio-vascular unit on a chip' would help accelerate understanding of pathophysiological mechanisms, identify targets and allow high throughput testing of potential interventions; Better molecular imaging probes to study different NVU cell types, determine molecular tissue changes and probe inflammatory processes; Use larger mammalian models, eg well characterised porcine models, since rodents have low white matter:grey matter ratio.
BBB	<ul style="list-style-type: none"> A dynamic complex structure whose dysfunction is a common feature of neurological diseases including cerebral SVD and related dementia syndromes (e.g. AD and VCI/VaD). Lack of understanding of: <ol style="list-style-type: none"> how cellular morphology relates to function the temporal changes and sequence of damage how BBB dysfunction leads to brain parenchymal lesions. 	<ul style="list-style-type: none"> Core set of reference standard techniques for preclinical, neuropathological and clinical studies; <i>In vivo</i> and <i>in vitro</i> methods to model small and transient BBB changes; More sensitive neuropathological methods to identify WMH as seen on MRI; New molecular imaging probes for pericytes and endothelial cell function status; More use of the retina routinely in rodent models (as in human SVDs) could help visualise arteriolar/venular, retinopathic and nerve fibre layer changes that could advance understanding of brain changes in rodent models (as suggested in human SVDs); Alternatives to gadolinium for human <i>in vivo</i> BBB imaging.
Hypoperfusion and ischaemia	<ul style="list-style-type: none"> Often poor characterisation in models Poor understanding of the influence of structural differences in perforating arterioles in different brain regions and arterial territories. The primary trigger, whether inflammation, altered flow, other, and their interactions. Is flow-metabolism coupling altered in SVD? 	<ul style="list-style-type: none"> Longitudinal investigations in models Better characterisation of tissue metabolic changes (eg pO₂, glucose, metabolites) (particularly white matter); More standard use of terminology for SVD in <i>in vivo</i> models and neuropathology, and for studying components of NVU <i>in vitro</i> would help, as has been implemented in clinical studies [3]
Inflammation	<ul style="list-style-type: none"> How do microglia, pericytes, perivascular macrophages, fibroblasts, oligodendrocytes all interact to maintain homeostasis? Are soluble inflammatory mediators (complement, chemokines, cytokines) involved in perivascular inflammation in SVD? What is the role of fibrosis in SVD? How is the matrix environment perturbed to influence cell function and signalling? 	<ul style="list-style-type: none"> Determine the contribution of inflammation in SVD and define whether there is a classic innate response and/or contribution of systemic inflammation or both Undertake longitudinal studies across models to profile microglial proliferation and migration and the broader molecular/cellular neuroinflammatory environment including measures of circulating immune cells. In relation to above a wider investigation of the 'mattisome'
White matter: axons, myelin sheaths	<ul style="list-style-type: none"> The role of oligodendrocytes and myelinated axons in the pathogenesis of SVD is unclear as is their interaction with other cells, such as endothelial cells. The extent of damage to myelinated axons in cortical grey matter in SVD is poorly defined The relationship of demyelination and axonal loss to CBF changes in SVD is unclear 	<ul style="list-style-type: none"> Comparative studies of potential SVD mechanisms across models, species, and diseases of white matter that have potential similarities to SVD (eg multiple sclerosis) using the most innovative molecular, cellular and imaging approaches Use MRI/DTI of white matter status as routinely as possible to link <i>in vivo</i> to tissue pathology more clearly; Link white matter pathology stages and burden to vascular pathology load and CBF alterations more clearly

Mechanism	Gaps in knowledge	Requirements for early advances in knowledge
<p>Perivascular and interstitial fluid drainage</p>	<ul style="list-style-type: none"> • To what extent are rodents relevant models of human drainage pathways and mechanisms? • What is the driving force for ISF clearance: <ul style="list-style-type: none"> a) vasomotion of cortical arteries?; b) perivascular innervation? c) does the smooth muscle action in veins have a functional role? • How does ISF clearance relate to SVD development or progression? • Does extracellular remodelling vary during the sleep-wake cycle? 	<ul style="list-style-type: none"> • Investigate integrity of architecture of myelinated axons in cortical grey matter and white matter • Determine how CSF and ISF and clearance pathways all relate to each other; • Determine if ISF and perivascular drainage vary with sleep-wake cycle; • Better methods to detect perivascular and ISF drainage in humans • Can CSF or ISF drainage pathways be targeted to inform treatment for SVD? • Does targeting of matrix proteins (TIMPs or MMPs) or vasomotion increase drainage?
<p>Neuro-glia-vascular mechanisms</p>	<ul style="list-style-type: none"> • How do vascular changes drive glial and neuronal dysfunction and damage? 	<ul style="list-style-type: none"> • Target white matter more in rodents; • Standardise anaesthetics and stimulation procedures; • Identify better ways to measure neuronal responses than blood oxygen dependent (BOLD) and related imaging methods (arterial spin labelling, blood volume measures, O2 metabolism, EEG and magnetoencephalography); • Expand cohort imaging similar to that achieved in the AD Neuroimaging Initiative; • Make more use of optogenetics and genetically encoded calcium indicators.